Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer

Lampropoulou, Dimitra Ioanna; Aravantinos, G.; Katifelis, Hector; Lazaris, Foivos; Laschos, Konstantinos; Theodosopoulos, Theodosios; Papadimitriou, Christos; Gazouli, Maria

doi:10.3233/cbm-182383

Cited by 13 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between rs3200401 polymorphism of MALAT1 in terms of drug efficacy and toxicity has been confirmed, and the rs3200401 CT genotype can be used as a toxicity biomarker 50 . The association between rs3200401 polymorphism of MALAT1 in terms of drug efficacy and toxicity has been confirmed, and the rs3200401 CT genotype can be used as a toxicity biomarker 30 . It can be seen that rs3200401 C and T alleles can change the structural characteristics of MALAT1 and reshape the expression level of cancer-related genes, thus participating in the occurrence and development of cancer 49 , 51 .…”

Section: Discussionmentioning

confidence: 87%

“…Some studies have shown that lncRNA SNPs are associated with cancer risk and are potential predictive biomarkers of cancer risk 30 . The association between rs3200401 polymorphism of MALAT1 in terms of drug efficacy and toxicity has been confirmed, and the rs3200401 CT genotype can be used as a toxicity biomarker 50 .…”

Section: Discussionmentioning

confidence: 99%

“…MALAT-1 was first discovered in a study of non-small cell lung cancer [23]. Since the discovery of MALAT1, it had played an important role in the occurrence, development, metastasis, drug resistance and clinical treatment of the disease [16,[24][25][26][27][28][29][30], especially in lung cancer. Moreover, many papers had reported the risk of MALAT1 polymorphisms and diseases susceptibility [31][32][33][34][35][36][37][38][39][40][41][42][43][44].…”

Section: Ivyspringmentioning

confidence: 99%

See 2 more Smart Citations

MALAT1 Polymorphisms and Lung Cancer Susceptibility in a Chinese Northeast Han Population

Tong¹,

Tong²,

He³

et al. 2022

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: LncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) was competitive endogenous RNA (ceRNA) involved in various molecular processes for metastasis development in lung cancer. Single nucleotide polymorphisms (SNPs) in MALAT1 gene might be predictive markers for lung cancer. In our study, we selected rs619586 and rs3200401 in MALAT1 gene to explore their effects on lung cancer susceptibility. Methods: The case-control study included 444 lung cancer cases and 460 healthy controls. Genotyping was performed by Taqman allelic discrimination method. Logistic regression, Student t-test, and Chi-square test (χ 2 ) were used to analyze the data. Results:The findings of the study showed that rs3200401 was significantly associated with the risk of non-small cell lung cancer (NSCLC) and lung squamous cell carcinoma (LUSC). Compared with homozygous CC genotype, CT heterozygous genotype decreased risk of NSCLC (P a = 0.034) and LUSC (P a = 0.025). In addition, no statistical association was detected between rs619586 and lung cancer susceptibility. The interactions between genes and cigarette smoking were discovered via crossover analysis. However, there were no remarkable gene-environment interactions in additive and multiplicative model. Conclusion: Rs3200401 in lncRNA MALAT1 was associated with the susceptibility of non-small-cell lung cancer and lung squamous cell carcinoma. The gene-environmental (cigarette smoking) interactions were not notable.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Ivyspringmentioning

confidence: 99%

See 1 more Smart Citation

MALAT1 Polymorphisms and Lung Cancer Susceptibility in a Chinese Northeast Han Population

Tong¹,

Tong²,

He³

et al. 2022

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…The upregulation of MALAT1 expression promotes the development, invasion and metastasis of CRC through multiple pathways and is associated with poor prognosis [39,40]. Lampropoulou et al showed that the rs3200401 CT + TT genotype was related with a significantly lower overall survival [41]. These studies suggested that the variation of rs3200401 may be related to the occurrence of CRC.…”

Section: Discussionmentioning

confidence: 99%

The Relationship between MALAT1 Polymorphism rs3200401 C > T and the Risk of Overall Cancer: A Meta-Analysis

Han

et al. 2022

Medicina

View full text Add to dashboard Cite

Background and Objectives: At present, the association between the long non-coding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) polymorphism rs3200401 C > T and cancer risk remain controversial. The aim of this meta-analysis was to assess the association between rs3200401 C > T and cancer susceptibility. Materials and Methods: The databases of PubMed, EMBASE and Web of Science were searched for literature published in English until 1 September 2021. The odd ratios (ORs) and 95% confidence intervals (CIs) were applied to evaluate the strength of association in five genetic models. Heterogeneity was assessed using the Q-test and I2 test. Begg’s funnel plot and Egger’s linear regression test were conducted to assess publication bias. Meta-regression analysis was used to explore potential sources of heterogeneity. Trial sequential analysis (TSA) was performed to validate the reliability of the results. Results: A total of 10 case–control studies involving 6630 cases and 7457 controls were included in this study. The pooled ORs showed no significant association between MALAT1 rs3200401 C > T and cancer risk in five genetic models. Similarly, the association was not found in the subgroups of control source, ethnicity and study quality. In the cancer type subgroup, the results demonstrated that the T allele increased the risk of colorectal cancer (CRC) compared with the C allele. (C vs. T: OR, 1.16; 95% CI, 1.01–1.33). Conclusion: In the current meta-analysis, we found no significant association between MALAT1 polymorphism rs3200401 C > T and overall cancer risk. However, the rs3200401 C > T may be linked to a higher risk of CRC, which needs more studies to be further confirmed.

show abstract

“…35 The CT genotype (rs3200410 genotypes include CC, CT, TT) of rs3200401 MALAT1 (Ensembl: ENSG00000251562) polymorphism could serve as a toxicity biomarker. 36 lncRNA SNHG6 (Ensembl: ENSG00000245910) promotes chemoresistance through ULK1 (Ensembl: ENSG00000177169)-induced autophagy by sponging miR-26a-5p in colorectal cancer cells. 37 lncRNA H19 (Ensembl: ENSG00000130600) overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 (Ensembl: ENSG00000143384) via miR-29b-3p.…”

Section: Discussionmentioning

confidence: 99%

Inferences of Individual Drug Response-Related Long Non-coding RNAs Based on Integrating Multi-omics Data in Breast Cancer

Cui

Kong

Peng

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Differences in individual drug responses are obstacles in breast cancer (BRCA) treatment, so predicting responses would help to plan treatment strategies. The accumulation of cancer molecular profiling and drug response data provide opportunities and challenges to identify novel molecular signatures and mechanisms of tumor responsiveness to drugs in BRCA. This study evaluated drug responses with a multi-omics integrated system that depended on long non-coding RNAs (lncRNAs). We identified drug response-related lncRNAs (DRlncs) by combining expression data of lncRNA, microRNA, messenger RNA, methylation levels, somatic mutations, and the survival data of cancer patients treated with drugs. We constructed an integrated and computational multi-omics approach to identify DRlncs for diverse chemotherapeutic drugs in BRCA. Some DRlncs were identified with Adriamycin, Cytoxan, Tamoxifen, and all samples for BRCA patients. These DRlncs showed specific features regarding both expression and computational accuracies. The DRlnc-gene co-expression networks were constructed and analyzed. Key DRlncs, such as HOXA-AS2 (Ensembl: ENSG00000253552), in the drug Adriamycin were characterized. The experimental analysis also suggested that HOXA-AS2 (Ensembl: ENSG00000253552) was a key DRlnc in Adriamycin drug resistance in BRCA patients. Some DRlncs were associated with survival and some specific functions. A possible mechanism of DRlnc HOXA-AS2 (Ensembl: ENSG00000253552) in the Adriamycin drug response for BRCA resistance was inferred. In summary, this study provides a framework for lncRNA-based evaluation of clinical drug responses in BRCA. Understanding the underlying molecular mechanisms of drug responses will facilitate improved responses to chemotherapy and outcomes of BRCA treatment.

show abstract

Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer

Cited by 13 publications

References 54 publications

MALAT1 Polymorphisms and Lung Cancer Susceptibility in a Chinese Northeast Han Population

MALAT1 Polymorphisms and Lung Cancer Susceptibility in a Chinese Northeast Han Population

The Relationship between MALAT1 Polymorphism rs3200401 C > T and the Risk of Overall Cancer: A Meta-Analysis

Inferences of Individual Drug Response-Related Long Non-coding RNAs Based on Integrating Multi-omics Data in Breast Cancer

Contact Info

Product

Resources

About